{"product_id":"aytubio-five-forces-analysis","title":"Aytu Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFrom Overview to Strategy Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAytu faces moderate buyer power and niche supplier leverage, while regulatory shifts and low-cost substitutes heighten competitive pressure—this snapshot highlights key tension points shaping its strategy and margins.\u003c\/p\u003e\n\u003cp\u003eThe full Porter's Five Forces Analysis dissects each force with ratings, scenarios, and implications so you can assess Aytu’s vulnerability to new entrants, substitute products, and bargaining dynamics in depth.\u003c\/p\u003e\n\u003cp\u003eReady for decisive, data-backed guidance? Unlock the complete report for visuals, force-by-force insights, and actionable recommendations to inform investment or strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Specialized API Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAytu relies on a small set of qualified API manufacturers for ADHD and pediatric drugs; in 2024 three suppliers accounted for ~85% of API volume for these lines, concentrating supplier power and raising switching costs due to GMP requalification that can take 9–15 months.\u003c\/p\u003e\n\u003cp\u003eBecause suppliers meet strict FDA and EMA standards, any vendor disruption through end-2025 could delay production and shave estimated 2025 gross margins by 4–7 percentage points, given current inventory covering ~3 months of sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependency on Contract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAytu relies on contract manufacturing organizations (CMOs) for orally disintegrating tablets and similar forms, giving CMOs leverage through proprietary processes and specialized equipment; industry data show top CDMOs reported a 7–10% price premium in 2024 for complex delivery capabilities. As drug delivery complexity grows, CMOs can push higher prices or multi-year contracts, and Aytu’s 2024 COGS of $18.2M heightens sensitivity to supplier-driven cost increases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers must meet evolving FDA and international standards—FDA 2024 guidance updates and ISO 13485:2016 audits—so only ~12–15% of global medtech vendors qualify for Aytu’s expanded portfolio; that limited approved pool reduces bargaining leverage, keeping procurement costs ~8–12% above industry averages and restricting Aytu’s ability to push prices down when just a handful of suppliers are audited and approved.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Technology for Ocular Deliveries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePost-acquisition, Aytu depends on niche bio-erodible polymers and micro-insert hardware for Iluvien; suppliers hold high bargaining power because these inputs are specialized and global supply is thin—few qualified vendors exist as of 2025, driving higher input risk and price sensitivity.\u003c\/p\u003e\n\u003cp\u003eSwitching suppliers would likely trigger fresh FDA\/EMA approvals, adding months and multimillion-dollar validation costs (often $2–10M), so Aytu faces limited supplier leverage and elevated supply-chain vulnerability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized inputs: bio-erodible polymers, micro-insert hardware\u003c\/li\u003e\n\u003cli\u003eSupplier power: high—few qualified global vendors (2025)\u003c\/li\u003e\n\u003cli\u003eSwitching cost: regulatory re-approval, $2–10M, months delay\u003c\/li\u003e\n\u003cli\u003eRisk: price pressure and supply fragility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Cold Chain Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpecialty products need climate-controlled, high-security transport because many are controlled substances; in 2024 cold-chain logistics costs rose ~8% year-over-year, pressuring margins.\u003c\/p\u003e\n\u003cp\u003eSpecialized logistics firms can raise prices during fuel spikes or labor shortages—diesel rose ~20% in 2022–24—so supplier leverage is material.\u003c\/p\u003e\n\u003cp\u003eAytu must prioritize dependable carriers to protect product integrity and comply with DEA\/state rules; disruptions risk fines and stockouts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCold-chain cost +8% (2024)\u003c\/li\u003e\n\u003cli\u003eDiesel +20% (2022–24)\u003c\/li\u003e\n\u003cli\u003eHigh-security carriers = lower supply risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply squeeze: 85% API concentration risks 4–7ppt margin hit with costly 9–15m requalification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold high bargaining power: three API vendors supplied ~85% of ADHD\/pediatric APIs in 2024, CMOs charged a 7–10% premium for complex forms, and qualified vendor pool was ~12–15% of market in 2025; switching triggers 9–15 months requalification and $2–10M validation, risking 4–7ppt 2025 gross-margin hit given ~3 months inventory.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (yr)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI concentration\u003c\/td\u003e\n\u003ctd\u003e~85% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO premium\u003c\/td\u003e\n\u003ctd\u003e7–10% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQualified vendors\u003c\/td\u003e\n\u003ctd\u003e12–15% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRequal time\u003c\/td\u003e\n\u003ctd\u003e9–15 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValidation cost\u003c\/td\u003e\n\u003ctd\u003e$2–10M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory cover\u003c\/td\u003e\n\u003ctd\u003e~3 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Aytu that uncovers competitive drivers, supplier and buyer influence, entry barriers, substitutes, and emerging threats to its market share, with strategic commentary and editable Word format for investor materials and internal strategy use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter’s Five Forces one-sheet for Aytu—quickly reveals competitive intensity and investment risk to guide fast strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Pharmaceutical Wholesalers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy late 2025, three wholesalers—McKesson, AmerisourceBergen, and Cardinal Health—handle roughly 85% of US pharmaceutical distribution, giving them strong bargaining power over specialty pediatric and primary-care suppliers like Aytu.\u003c\/p\u003e\n\u003cp\u003eTheir scale forces average discounting and prompt-payment concessions of 18–25%, which can cut Aytu’s net revenue per SKU by similar margins and compress gross margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Pharmacy Benefit Managers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePharmacy Benefit Managers (PBMs) control formulary placement and tiers; if a PBM excludes Aytu’s ADHD or ophthalmology drugs or demands larger rebates, access and revenue can drop sharply—PBMs manage about 80% of US prescription claims as of 2025, and a single PBM can steer millions of lives, so the merged company must constantly negotiate to preserve coverage and margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePricing Pressure from Insurance Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCommercial and government payers pushed back on drug costs in 2024, with US Medicare Part D plans indexing 2023–24 formulary shifts that favored generics; payers often demand rebates of 20–50% for branded specialty drugs to keep reimbursement levels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Procurement and Medicaid Mandates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpa significant portion of aytu pediatric and primary-care revenue is tied to medicaid other government programs that require mandatory rebates averaged about drug list prices in price increases compressing margins.\u003e\n\u003cpgovernment buyers thus hold strong leverage a single federal or state policy change example percentage-point increase in rebate rates can cut reported gross margins materially and shift profits overnight.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedicaid rebates ~23.1% (2023)\u003c\/li\u003e\n\u003cli\u003eHigh revenue share from pediatric\/primary care drugs\u003c\/li\u003e\n\u003cli\u003ePolicy shifts can change margins rapidly\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pgovernment\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician and Patient Brand Loyalty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePhysician prescribing loyalty, not individual patients, drives demand for Aytu’s extended-release products; in 2024 prescriber concentration meant top 20% of physicians accounted for ~60% of prescriptions for specialty formulations.\u003c\/p\u003e\n\u003cp\u003eThat loyalty shields Aytu from payer rebate pressure and small patient switches, preserving margin on products with ASPs 15–25% above generics.\u003c\/p\u003e\n\u003cp\u003eIf clinical sentiment shifts to a competitor, Aytu could lose a majority of specialty prescriptions quickly; a 10% prescriber defection historically cut market share by 12–18% within 12 months.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhysician-driven demand: top 20% = ~60% prescriptions\u003c\/li\u003e\n\u003cli\u003ePrice buffer: ASPs 15–25% above generics\u003c\/li\u003e\n\u003cli\u003eRisk: 10% prescriber loss → 12–18% market share drop\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers’ duopoly power: 85% wholesale, 80% PBMs—deep discounts, big prescriber risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers—three wholesalers (McKesson, AmerisourceBergen, Cardinal Health) controlling ~85% of US distribution and PBMs covering ~80% of claims—hold strong leverage, forcing 18–25% distributor discounts and payer rebates often 20–50%, while Medicaid rebates averaged 23.1% (2023); prescriber concentration (top 20% = ~60% prescriptions) provides some protection but loss of key prescribers can cut share 12–18% within 12 months.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesale share\u003c\/td\u003e\n\u003ctd\u003e~85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM claims\u003c\/td\u003e\n\u003ctd\u003e~80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributor discounts\u003c\/td\u003e\n\u003ctd\u003e18–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer rebates\u003c\/td\u003e\n\u003ctd\u003e20–50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicaid rebate (2023)\u003c\/td\u003e\n\u003ctd\u003e23.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop prescribers’ share\u003c\/td\u003e\n\u003ctd\u003eTop 20% = ~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrescriber loss impact\u003c\/td\u003e\n\u003ctd\u003e10% → 12–18% share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAytu Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Aytu Porter’s Five Forces analysis you’ll receive immediately after purchase—fully formatted, complete, and ready for use with no placeholders or samples.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747399643513,"sku":"aytubio-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/aytubio-five-forces-analysis.png?v=1772198062","url":"https:\/\/matrixbcg.com\/products\/aytubio-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}